Education
About Us
Working with TipRanks
Follow Us
X4 Pharmaceuticals Inc (XFOR)
NASDAQ:XFOR
Top Page
X4 Pharmaceuticals
(NASDAQ:XFOR)
38Underperform
Positive Factors
Financial Performance
The company reported total revenue of $1.4M, compared to the consensus estimate of $1.06M, and a net income of $0.20 per share, compared to the consensus estimated a net loss of $0.18 per share.
Revenue Growth
Xolremdi revenues demonstrate strongest quarter since launch.
Strategic Agreements
X4 entered into an exclusive licensing agreement with Norgine Pharmaceuticals for the commercialization of Xolremdi in Europe, Australia, and New Zealand, with potential E.U. approval in 1H26.
Negative Factors
Capital Requirements
Despite the collaboration, additional capital is still considered necessary to provide sufficient runway to topline data from the P3 4WARD trial.
Commercial Challenges
The longer-than-expected time to diagnose and initiate therapy for new WHIM patients and the high commercial cost to onboard a patient are challenges faced by the company.
Market Adoption
Market adoption of the drug has not been as robust as expected.
X4 Pharmaceuticals (XFOR) vs. S&P 500 (SPY)
Market Cap
$30.88M
Dividend YieldN/A
Average Volume (3M)74.25K
Price to Earnings (P/E)―
Beta (1Y)2.09
Revenue GrowthN/A
EPS Growth69.37%
CountryUS
Employees143
SectorHealthcare
Sector Strength70
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.56
Shares Outstanding5,788,746
10 Day Avg. Volume100,043
30 Day Avg. Volume74,251
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap4.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit70.96
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2.70Price Target Upside-37.35% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering5
X4 Pharmaceuticals Business Overview & Revenue Model
Company DescriptionX4 Pharmaceuticals, Inc. (XFOR) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics aimed at treating rare diseases. The company's primary focus is on diseases characterized by disruptions in immune cell trafficking, including certain types of primary immunodeficiencies. X4's lead product candidate, mavorixafor, is being developed to treat a range of conditions linked to this mechanism, such as WHIM syndrome, a rare immune disorder.
How the Company Makes MoneyX4 Pharmaceuticals generates revenue primarily through the development and commercialization of its pipeline of drug candidates. The company aims to bring its lead product, mavorixafor, to market, which is expected to be a key revenue driver upon approval. Revenue is also derived from strategic collaborations and partnerships with other pharmaceutical companies, which may include milestone payments, research funding, and royalties. Additionally, X4 may earn revenue through licensing agreements for its proprietary technologies and therapies. The company's focus on rare diseases often allows for orphan drug designations, which can provide market exclusivity and potential pricing power in niche markets.
X4 Pharmaceuticals Financial Statement Overview
Summary
X4 Pharmaceuticals faces significant challenges in achieving profitability and positive cash flow. While there are some indicators of improvement, such as a positive gross profit margin in 2024, the company struggles with consistent losses and substantial cash outflows. Its balance sheet shows a reasonable cash position, but declining stockholders' equity is a concern. The financial stability and future growth prospects are uncertain, requiring careful management and strategic planning.Income Statement
X4 Pharmaceuticals has shown consistent losses over the years, with negative net income and EBIT margins. The revenue growth is minimal, only appearing in 2020 and 2024. Gross profit margin is positive in 2024, indicating some improvement. However, the overall profitability and revenue generation remain challenging.35
Negative
Balance Sheet
The company's debt-to-equity ratio is low due to minimal debt, and it maintains a reasonable equity ratio. However, the return on equity is negative due to consistent net losses. The balance sheet indicates a stable cash position but a significant decline in stockholders' equity over time, which is concerning.45
Neutral
Cash Flow
X4 Pharmaceuticals is experiencing substantial negative free cash flow, with declining operating cash flow. The cash flow ratios are weak due to negative net income. However, the company maintains positive financing cash flow, likely helping to manage its cash position.40
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 2.56M | 0.00 | 0.00 | 0.00 | 3.00M | Gross Profit |
| 1.76M | -2.00M | -1.99M | -1.89M | 3.00M | EBIT |
| -36.40M | -107.52M | -87.57M | -85.11M | -59.87M | EBITDA |
| -36.40M | -107.10M | -87.57M | -85.11M | -58.06M | Net Income Common Stockholders |
| -37.45M | -101.17M | -93.87M | -88.70M | -62.13M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 102.06M | 114.22M | 121.72M | 81.79M | 78.71M | Total Assets |
| 146.45M | 147.26M | 155.59M | 117.18M | 122.87M | Total Debt |
| 2.66M | 58.28M | 38.42M | 39.78M | 38.45M | Net Debt |
| -53.04M | -40.94M | -83.30M | -42.00M | -40.26M | Total Liabilities |
| 124.30M | 96.16M | 81.53M | 52.76M | 50.07M | Stockholders Equity |
| 22.15M | 51.10M | 74.05M | 64.41M | 72.80M |
| Cash Flow | Free Cash Flow | |||
| -131.23M | -96.57M | -77.20M | -71.52M | -60.18M | Operating Cash Flow |
| -130.90M | -96.51M | -77.10M | -70.91M | -58.82M | Investing Cash Flow |
| 66.99M | -14.88M | -103.00K | -615.00K | -1.36M | Financing Cash Flow |
| 20.29M | 88.52M | 117.23M | 74.25M | 12.39M |
X4 Pharmaceuticals Technical Analysis
Negative
4.31
Price Trends
8.54
Negative
13.11
Negative
15.72
Negative
Market Momentum
-1.06
Negative
24.11
Positive
15.16
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XFOR, the sentiment is Negative. The current price of 4.31 is below the 20-day moving average (MA) of 5.95, below the 50-day MA of 8.54, and below the 200-day MA of 15.72, indicating a bearish trend. The MACD of -1.06 indicates Negative momentum. The RSI at 24.11 is Positive, neither overbought nor oversold. The STOCH value of 15.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XFOR.
X4 Pharmaceuticals Risk Analysis
X4 Pharmaceuticals disclosed 64 risk factors in its most recent earnings report. X4 Pharmaceuticals reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
X4 Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $39.64M | ― | -214.02% | ― | ― | 53.92% | |
52 Neutral | $5.38B | 3.59 | -41.63% | 2.87% | 17.72% | 1.87% | |
51 Neutral | $58.24M | ― | -46.63% | ― | 4.58% | 10.59% | |
45 Neutral | $34.68M | ― | 108.28% | ― | ― | 41.01% | |
39 Underperform | $52.31M | ― | -79.26% | ― | ― | 14.06% | |
38 Underperform | $30.88M | ― | -102.26% | ― | ― | 69.37% | |
34 Underperform | $57.84M | ― | 41.08% | ― | -0.55% | 49.85% |
* Healthcare Sector Average
Performance Comparison
XFOR
X4 Pharmaceuticals
4.31
-28.09
-86.70%
KPTI
Karyopharm Therapeutics
6.75
-9.45
-58.33%
NRXP
NRX Pharmaceuticals
2.12
0.06
2.91%
RPTX
Repare Therapeutics
1.37
-1.98
-59.10%
XLO
Xilio Therapeutics
0.76
-0.29
-27.62%
PEPG
PepGen Inc.
1.57
-12.92
-89.16%
X4 Pharmaceuticals Earnings Call Summary
Earnings Call Date:Mar 25, 2025
(Q4-2024)
| % Change Since: -51.30%|
Next Earnings Date:May 01, 2025
Earnings Call Sentiment Positive
X4 Pharmaceuticals showed strong progress with the launch of XOLREMDI and international expansion efforts. Positive clinical trial results and strategic restructuring indicate potential for future growth. However, the company faces challenges with net losses, market penetration, and adjustments in clinical trial protocols.Q4-2024 Updates
Positive Updates
Successful Launch of XOLREMDI
X4 Pharmaceuticals launched XOLREMDI for WHIM syndrome, achieving $2.5 million in sales despite only being on the market for 7.5 months since mid-May 2024.
Positive Phase 2 Clinical Trial Results
The Phase 2 trial for mavorixafor in chronic neutropenia showed that the drug was well tolerated and increased mean absolute neutrophil counts, reducing the use of G-CSF.
Progress in International Markets
X4 Pharmaceuticals expanded its reach with two international partnerships and had its MAA accepted by the EMA for mavorixafor.
Strategic Restructuring for Cost Efficiency
A strategic restructuring was implemented to decrease spending by $30 million to $35 million annually, focusing on maximizing the opportunity for mavorixafor in chronic neutropenia.
Negative Updates
Net Loss Despite Revenue
X4 Pharmaceuticals reported a net loss of $37.5 million for 2024, even with revenue from the sale of a priority review voucher for $105 million.
Uncertainty and Challenges in Market Penetration
Despite positive developments, there are challenges in diagnosing WHIM syndrome and building demand for XOLREMDI, requiring extensive educational efforts.
Shift in Phase 3 Trial Protocol
The 4WARD Phase 3 trial protocol was adjusted to focus on patients with ANC below 1,000 cells per microliter, potentially affecting enrollment timelines.
Company Guidance
During the X4 Pharmaceuticals Fourth Quarter and Full Year 2024 Financial and Operating Results Conference Call, key metrics highlighted included the 2024 XOLREMDI sales topping $2.5 million in the 7.5 months since its mid-May launch for the treatment of WHIM syndrome. The company engaged with top-tier immunologists and hematologists, with efforts expected to increase patient finding and prescription rates. The company reported net XOLREMDI revenues of $1.4 million for the fourth quarter and $2.6 million for the full year. Research and Development (R&D) expenditures were $21.7 million for Q4 and $81.6 million for the year, while Selling, General and Administrative (SG&A) expenses were $15.1 million for Q4 and $61.5 million for the year. The net loss was $39.8 million for Q4 and $37.5 million for the full year, noting a significant income from a priority review voucher sale. Moving forward, the company has refined its global pivotal Phase 3 CN trial protocol and aims for full enrollment by Q3 or Q4 2025, with top-line data expected in the second half of 2026. The company ended 2024 with nearly $103 million in cash and cash equivalents, projecting sufficient funds to support operations into the first half of 2026.X4 Pharmaceuticals Corporate Events
Stock SplitBusiness Operations and StrategyFinancial Disclosures
X4 Pharmaceuticals Reports Q1 2025 Financial Results
Positive
May 1, 2025
On May 1, 2025, X4 Pharmaceuticals reported its financial results for the first quarter of 2025, highlighting significant progress in its clinical trials and commercialization efforts. The company is advancing its Phase 3 4WARD trial for chronic neutropenia and has seen a positive response to its drug XOLREMDI in the U.S. market. Strategic restructuring and international partnerships aim to maximize the potential of mavorixafor, while a recent reverse stock split and improved financial performance position the company for future growth.
Spark’s Take on XFOR Stock
According to Spark, TipRanks’ AI Analyst, XFOR is a Neutral.
X4 Pharmaceuticals’ overall stock score reflects significant challenges in financial performance, as indicated by consistent losses and weak cash flow. Technical indicators suggest downward momentum, and valuation metrics are unfavorable with a negative P/E ratio. While the earnings call presented some positive developments, the net losses and market penetration issues remain major concerns. The strategic restructuring is a step towards cost efficiency but adds uncertainty to the company’s future performance.
To see Spark’s full report on XFOR stock, click here.
Business Operations and Strategy
X4 Pharmaceuticals Announces Strategic Restructuring Plans
Negative
Feb 6, 2025
X4 Pharmaceuticals announced a strategic restructuring on February 6, 2025, involving a workforce reduction of approximately 30%, the closure of its Vienna facility, and a focus on advancing mavorixafor for chronic neutropenia. This restructuring aims to decrease annual spending by $30-35 million and extend the company’s cash runway into the first half of 2026, by streamlining operations to enhance the global market opportunity for mavorixafor.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.